TAVI Access: Does the Route Really Matter?
"A single-center study sheds light on whether transfemoral or transapical access impacts mortality in TAVI procedures."
Transcatheter aortic valve implantation (TAVI) has revolutionized the treatment of severe aortic stenosis, offering a less invasive alternative to traditional open-heart surgery for high-risk patients. While TAVI's benefits are clear, debates persist regarding the optimal access route—transfemoral (TF) or transapical (TA).
The transfemoral approach, accessing the heart through the femoral artery in the leg, is often preferred due to its minimally invasive nature. However, when TF isn't feasible, the transapical approach, which involves a small incision in the chest to access the heart directly, becomes necessary. Some studies have suggested that TA-TAVI is associated with higher mortality rates compared to TF-TAVI, raising concerns about whether the access route itself contributes to increased risk.
This article explores a recent single-center study that investigated the impact of access route on TAVI outcomes. By analyzing data from 1130 patients, researchers aimed to determine whether the increased mortality observed after TA-TAVI is truly caused by the access mode or if it reflects the higher-risk profile of patients undergoing this approach. This analysis helps to clarify the factors influencing TAVI success and guides clinical decision-making.
Choosing a TAVI Access Route
Transfemoral access is described as the optimal TAVI approach, while alternative routes can make valve replacement possible for patients who are not eligible for transfemoral treatment sciencedirect.com. For patients unsuitable for transfemoral TAVI, strategies include transaxillary, transapical, and transaortic access pmc.ncbi.nlm.nih.gov. Reviews assess these routes in terms of indications, safety, efficacy, and complications, but the supplied sources do not provide a single comparative outcome figure.
Transfemoral TAVI and Its Limits
Transfemoral access is the preferred route when feasible, with its minimally invasive nature, reduced procedural morbidity, and shorter recovery times cited as advantages mdpi.com. However, peripheral vascular disease or anatomical constraints can make this route unsuitable for a significant proportion of patients pcronline.com. Vascular access complications are clinically relevant: one review reports that they occur in up to one fourth of patients and are strongly associated with adverse outcomes pmc.ncbi.nlm.nih.gov.
From Early Access Experiments to a Default Route
An early TAVI technique used antegrade trans-septal access and a venous-arterial loop to pass a rigid valve delivery system across the atrial septum and mitral valve to reach the stenotic aortic valve; the approach was difficult and carried a considerable risk of mitral leaflet damage sciencedirect.com. TAVI reached its first clinical application in 2002, following a preclinical phase in which pioneers developed the concept and prototype valves despite strong headwind link.springer.com. The Netherlands was an early clinical and scientific adopter in 2005 link.springer.com. Later, transfemoral access was described as the default route, with experienced teams reporting procedures under an hour, early mobilisation, and shorter hospital stays .
TAVI Access: Unpacking the Research
The study, conducted at a single center, reviewed data from 1130 patients undergoing TAVI between 2009 and 2016. Of these, 619 patients underwent TF-TAVI, while 511 received TA-TAVI. Researchers meticulously compared 30-day mortality and major morbidity rates between the two groups, using the Valve Academic Research Consortium 2 (VARC-2) criteria to ensure standardized assessment.
- Unadjusted 30-day mortality was higher in TA-TAVI patients, but this difference wasn't statistically significant.
- Multivariate analysis revealed that the logistic EuroSCORE and institutional experience were independent predictors of 30-day mortality, while the access mode was not.
- Major access-site complications occurred at similar rates in both groups.
- After adjusting for risk factors, long-term mortality rates were also similar between TF-TAVI and TA-TAVI patients.
Access, Outcomes, and Procedural Guidance
A 2026 report on a single Belgian centre’s 15-year TAVI experience says the centre gradually moved away from transapical access, which it describes as associated with high bleeding rates and worse overall outcomes doi.org. A separate study reports that logistic EuroSCORE and institutional experience, but not access mode, were independent predictors of 30-day mortality in its multivariate analysis doi.org. Research published in 2025 is also evaluating ultrasound-guided versus angiographic-roadmap femoral access by comparing vascular complications and bleeding at the main access site link.springer.com. The supplied snippet describes that study’s question and methods, but does not state its results.
The Bigger Picture: Patient Risk vs. Access Route
This study reinforces the importance of considering patient-specific risk factors when evaluating TAVI outcomes. While the transapical approach may be necessary for certain patients, it's crucial to recognize that these individuals often have more complex medical histories.
Questions Shaping TAVI’s Future
A 2026 narrative review frames future TAVI challenges around clinical outcomes, prosthesis selection, durability, and valve-in-valve procedures mdpi.com. It aims to summarize the evidence currently available in these areas and discuss future directions. The supplied source description does not specify particular new access technologies or predict how access-route use will change.
Real-World Pathways and Access-Site Closure
A 2025 study set out to assess the safety and efficacy of a comprehensive, minimalistic TAVI approach using all available devices in an all-comers, real-world population link.springer.com. Its background notes that earlier optimized pathways had considered specific devices and selected populations link.springer.com. Separately, a study published in 2024 compared two vascular closure device strategies for achieving haemostasis after transfemoral TAVI, addressing a field where randomized-trial data remain scarce academic.oup.com. The supplied source descriptions do not report the studies’ outcome results.
The study also highlights the impact of institutional experience on TAVI success. As medical centers perform more TAVI procedures, their teams become more skilled at patient selection, procedural techniques, and complication management, leading to improved outcomes regardless of the access route.
Ultimately, the choice between transfemoral and transapical TAVI should be based on a comprehensive assessment of the patient's individual needs and anatomical considerations, with careful attention to risk mitigation and optimization of procedural expertise. By focusing on these factors, healthcare professionals can ensure the best possible outcomes for all TAVI patients.